Dr. Shune is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2330 Shawnee Mission Pkwy
Ste 210
Westwood, KS 66205Phone+1 913-588-6030Fax+1 913-588-4085
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2010 - 2013- University of MinnesotaResidency, Internal Medicine, 2007 - 2010
Istanbul University FomClass of 2004
Certifications & Licensure
MO State Medical License 2021 - 2026
KS State Medical License 2014 - 2025
Clinical Trials
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients Start of enrollment: 2021 Nov 02
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 4 citationsSafety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu
Blood. 2025-01-02 - BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma.Aliya Rashid, William Wesson, Al-Ola Abdallah, Jordan Snyder, Priyanka Venkatesh
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-01 - 1 citationsPatient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from...Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf
The Lancet. Haematology. 2025-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
